Top stories in hematology/oncology: New guideline for testicular cancer, therapeutic cancer vaccine being tested

The top stories in hematology/oncology last week were two interviews, one focusing on a new guideline released by the American Urological Association for the diagnosis and treatment of patients with early-stage testicular cancer and one about a novel vaccine being tested that uses immune stimulants to inhibit cancer cell growth among patients with advanced-stage lymphoma.

Other highlights included trial results that found pretreatment factors and response variables influenced venetoclax efficacy in relapsed chronic lymphocytic leukemia, a study that suggested colorectal cancer subtypes could help predict best initial treatment option and a Q&A centered on study results that indicated a minimally invasive surgical technique restored erectile function among most of a small cohort of men who underwent radical prostatectomy for prostate cancer.

New American Urological Association guideline offers ‘relevant blueprint’ for testicular cancer diagnosis, treatment

The American Urological Association has released a new guideline on the diagnosis and treatment of early-stage testicular cancer. Read more.

Therapeutic vaccine could improve checkpoint blockade efficacy for patients with cancer

Researchers at Icahn School of Medicine at Mount Sinai have developed a novel vaccine that uses immune stimulants to inhibit cancer cell growth among patients with advanced-stage lymphoma. Read more.

Pretreatment factors, response variables influence venetoclax efficacy in relapsed chronic lymphocytic leukemia

Pretreatment factors and depth of response appeared associated with duration of response to venetoclax among patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma, according to results of a prospective trial published in Blood. Read more.

Colorectal cancer subtypes could help predict best initial treatment option

Consensus molecular subtype classification demonstrated potential clinical utility as an independent prognostic factor for patients with metastatic colorectal cancer who receive first-line therapy, according to results of a prospective phase 3 trial published in Journal of Clinical Oncology. Read more.

Technique shows potential in restoring erectile function after cancer-related radical prostatectomy

A minimally invasive surgical technique restored erectile function among most of a small cohort of men who underwent radical prostatectomy for prostate cancer, according to study results. Read more.

 

 

The top stories in hematology/oncology last week were two interviews, one focusing on a new guideline released by the American Urological Association for the diagnosis and treatment of patients with early-stage testicular cancer and one about a novel vaccine being tested that uses immune stimulants to inhibit cancer cell growth among patients with advanced-stage lymphoma.

Other highlights included trial results that found pretreatment factors and response variables influenced venetoclax efficacy in relapsed chronic lymphocytic leukemia, a study that suggested colorectal cancer subtypes could help predict best initial treatment option and a Q&A centered on study results that indicated a minimally invasive surgical technique restored erectile function among most of a small cohort of men who underwent radical prostatectomy for prostate cancer.

New American Urological Association guideline offers ‘relevant blueprint’ for testicular cancer diagnosis, treatment

The American Urological Association has released a new guideline on the diagnosis and treatment of early-stage testicular cancer. Read more.

Therapeutic vaccine could improve checkpoint blockade efficacy for patients with cancer

Researchers at Icahn School of Medicine at Mount Sinai have developed a novel vaccine that uses immune stimulants to inhibit cancer cell growth among patients with advanced-stage lymphoma. Read more.

Pretreatment factors, response variables influence venetoclax efficacy in relapsed chronic lymphocytic leukemia

Pretreatment factors and depth of response appeared associated with duration of response to venetoclax among patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma, according to results of a prospective trial published in Blood. Read more.

Colorectal cancer subtypes could help predict best initial treatment option

Consensus molecular subtype classification demonstrated potential clinical utility as an independent prognostic factor for patients with metastatic colorectal cancer who receive first-line therapy, according to results of a prospective phase 3 trial published in Journal of Clinical Oncology. Read more.

Technique shows potential in restoring erectile function after cancer-related radical prostatectomy

A minimally invasive surgical technique restored erectile function among most of a small cohort of men who underwent radical prostatectomy for prostate cancer, according to study results. Read more.